PL243119B1 - Rozpuszczalne w wodzie modyfikowane pochodne aminokwasowe nadające się do leczenia chorób o podłożu neurologicznym oraz zaburzeń psychiatrycznych - Google Patents

Rozpuszczalne w wodzie modyfikowane pochodne aminokwasowe nadające się do leczenia chorób o podłożu neurologicznym oraz zaburzeń psychiatrycznych Download PDF

Info

Publication number
PL243119B1
PL243119B1 PL433567A PL43356720A PL243119B1 PL 243119 B1 PL243119 B1 PL 243119B1 PL 433567 A PL433567 A PL 433567A PL 43356720 A PL43356720 A PL 43356720A PL 243119 B1 PL243119 B1 PL 243119B1
Authority
PL
Poland
Prior art keywords
propanamide
compound
dcm
mmol
meoh
Prior art date
Application number
PL433567A
Other languages
English (en)
Polish (pl)
Other versions
PL433567A1 (pl
Inventor
Krzysztof KAMIŃSKI
Krzysztof Kamiński
Michał ABRAM
Michał Abram
Marcin JAKUBIEC
Marcin Jakubiec
Anna RAPACZ
Anna Rapacz
Szczepan MOGILSKI
Szczepan Mogilski
Gniewomir LATACZ
Gniewomir Latacz
Marta STRUGA
Marta Struga
Original Assignee
Univ Jagiellonski
Univ Warszawski Medyczny
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Jagiellonski, Univ Warszawski Medyczny filed Critical Univ Jagiellonski
Priority to PL433567A priority Critical patent/PL243119B1/pl
Priority to ES21732998T priority patent/ES3020435T3/es
Priority to CN202180038326.1A priority patent/CN115715219B/zh
Priority to PL21732998.6T priority patent/PL4135840T3/pl
Priority to EP24215754.3A priority patent/EP4527384A3/en
Priority to US17/996,235 priority patent/US20230192608A1/en
Priority to CA3175613A priority patent/CA3175613A1/en
Priority to EP21732998.6A priority patent/EP4135840B1/en
Priority to PCT/PL2021/050026 priority patent/WO2021210997A1/en
Publication of PL433567A1 publication Critical patent/PL433567A1/pl
Publication of PL243119B1 publication Critical patent/PL243119B1/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2632-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36Oxygen or sulfur atoms
    • C07D207/402,5-Pyrrolidine-diones
    • C07D207/4162,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL433567A 2020-04-16 2020-04-16 Rozpuszczalne w wodzie modyfikowane pochodne aminokwasowe nadające się do leczenia chorób o podłożu neurologicznym oraz zaburzeń psychiatrycznych PL243119B1 (pl)

Priority Applications (9)

Application Number Priority Date Filing Date Title
PL433567A PL243119B1 (pl) 2020-04-16 2020-04-16 Rozpuszczalne w wodzie modyfikowane pochodne aminokwasowe nadające się do leczenia chorób o podłożu neurologicznym oraz zaburzeń psychiatrycznych
ES21732998T ES3020435T3 (en) 2020-04-16 2021-04-16 Water-soluble, modified amino acid derivatives for the treatment of neurological diseases and selected psychiatric disorders
CN202180038326.1A CN115715219B (zh) 2020-04-16 2021-04-16 用于治疗神经系统疾病和选择的精神疾患的水溶性、修饰的氨基酸衍生物
PL21732998.6T PL4135840T3 (pl) 2020-04-16 2021-04-16 Rozpuszczalne w wodzie modyfikowane pochodne aminokwasowe do leczenia chorób o podłożu neurologicznym oraz wybranych zaburzeń psychiatrycznych
EP24215754.3A EP4527384A3 (en) 2020-04-16 2021-04-16 Water-soluble, modified amino acid derivatives for the treatment of neurological diseases and selected psychiatric disorders
US17/996,235 US20230192608A1 (en) 2020-04-16 2021-04-16 Water-soluble, modified amino acid derivatives for treatment of neurological diseases, and selected psychiatric disorders
CA3175613A CA3175613A1 (en) 2020-04-16 2021-04-16 Water-soluble, modified amino acid derivatives for treatment of neurological diseases, and selected psychiatric disorders
EP21732998.6A EP4135840B1 (en) 2020-04-16 2021-04-16 Water-soluble, modified amino acid derivatives for the treatment of neurological diseases and selected psychiatric disorders
PCT/PL2021/050026 WO2021210997A1 (en) 2020-04-16 2021-04-16 Water-soluble, modified amino acid derivatives for treatment of neurological diseases, and selected psychiatric disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL433567A PL243119B1 (pl) 2020-04-16 2020-04-16 Rozpuszczalne w wodzie modyfikowane pochodne aminokwasowe nadające się do leczenia chorób o podłożu neurologicznym oraz zaburzeń psychiatrycznych

Publications (2)

Publication Number Publication Date
PL433567A1 PL433567A1 (pl) 2021-10-18
PL243119B1 true PL243119B1 (pl) 2023-06-26

Family

ID=76483335

Family Applications (2)

Application Number Title Priority Date Filing Date
PL433567A PL243119B1 (pl) 2020-04-16 2020-04-16 Rozpuszczalne w wodzie modyfikowane pochodne aminokwasowe nadające się do leczenia chorób o podłożu neurologicznym oraz zaburzeń psychiatrycznych
PL21732998.6T PL4135840T3 (pl) 2020-04-16 2021-04-16 Rozpuszczalne w wodzie modyfikowane pochodne aminokwasowe do leczenia chorób o podłożu neurologicznym oraz wybranych zaburzeń psychiatrycznych

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL21732998.6T PL4135840T3 (pl) 2020-04-16 2021-04-16 Rozpuszczalne w wodzie modyfikowane pochodne aminokwasowe do leczenia chorób o podłożu neurologicznym oraz wybranych zaburzeń psychiatrycznych

Country Status (7)

Country Link
US (1) US20230192608A1 (es)
EP (2) EP4527384A3 (es)
CN (1) CN115715219B (es)
CA (1) CA3175613A1 (es)
ES (1) ES3020435T3 (es)
PL (2) PL243119B1 (es)
WO (1) WO2021210997A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL240297B1 (pl) 2019-04-16 2022-03-14 Univ Jagiellonski Modyfikowane pochodne aminokwasowe do leczenia chorób o podłożu neurologicznym oraz wybranych zaburzeń psychiatrycznych

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW288010B (es) * 1992-03-05 1996-10-11 Pfizer
PL240297B1 (pl) * 2019-04-16 2022-03-14 Univ Jagiellonski Modyfikowane pochodne aminokwasowe do leczenia chorób o podłożu neurologicznym oraz wybranych zaburzeń psychiatrycznych

Also Published As

Publication number Publication date
EP4135840A1 (en) 2023-02-22
CN115715219A (zh) 2023-02-24
PL4135840T3 (pl) 2025-05-12
EP4135840B1 (en) 2025-01-08
EP4527384A3 (en) 2025-07-02
CN115715219B (zh) 2026-01-06
CA3175613A1 (en) 2021-10-21
EP4527384A2 (en) 2025-03-26
PL433567A1 (pl) 2021-10-18
US20230192608A1 (en) 2023-06-22
WO2021210997A1 (en) 2021-10-21
ES3020435T3 (en) 2025-05-22

Similar Documents

Publication Publication Date Title
KR0179661B1 (ko) N-페닐알킬 치환된 알파-아미노 카복스아미드 유도체 및 이를 포함하는 약제학적 조성물 및 이의 제조방법
US12331019B2 (en) Modified amino acid derivatives for the treatment of neurological diseases and selected psychiatric disorders
US5731348A (en) Alkylcarboxy amino acids-modulators of the kainate receptor
EP0731085A1 (en) Stilbene derivatives and pharmaceutical compositions containing them
KR20010108032A (ko) 갑상선 수용체 리간드
FI94955C (fi) Menetelmä uusien terapeuttisesti aktiivisten substituoitujen 7-hydroksi-2,3,4,5-tetrahydro-1H-3-bentsatsepiinien karbamiinihappoestereiden valmistamiseksi
PL243119B1 (pl) Rozpuszczalne w wodzie modyfikowane pochodne aminokwasowe nadające się do leczenia chorób o podłożu neurologicznym oraz zaburzeń psychiatrycznych
JP2022522949A (ja) (2,5-ジオキソピロリジン-1-イル)(フェニル)-アセトアミド誘導体、および神経疾患の処置におけるその使用
LT3960B (en) Process for preparing hypoglycemic compounds
Weigl et al. Synthesis of chiral non-racemic 3-(dioxopiperazin-2-yl) propionic acid derivatives
US20060135785A1 (en) Alpha-phenyl acetanilide derivatives having an acat inhibiting activity and the therapeutic application thereof
PL175707B1 (pl) Nowe estry 1-aryloksy-3-alkiloamino-2-propanolu
US20250042848A1 (en) DEUTERATED FUNCTIONALIZED DERIVATIVES OF alpha-ALANINE, IN PARTICULAR FOR THE TREATMENT OF NEUROLOGICAL DISEASES
HK40082537A (en) Water-soluble, modified amino acid derivatives for treatment of neurological diseases and selected psychiatric disorders
HK40064412A (en) Modified amino acid derivatives for the treatment of neurological diseases and selected psychiatric disorders
CN119661447A (zh) 一种(3r,6r)-1-十二烷基-3,6-二异丁基哌嗪-2,5-二酮的制备方法